KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Other financing activities (2016 - 2025)

Pfizer (PFE) has disclosed Other financing activities for 17 consecutive years, with -$43.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Other financing activities fell 207.14% to -$43.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$458.0 million, a 2.35% increase, with the full-year FY2025 number at -$458.0 million, up 2.35% from a year prior.
  • Other financing activities was -$43.0 million for Q4 2025 at Pfizer, down from -$38.0 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $154.0 million in Q3 2022 to a low of -$610.0 million in Q2 2021.
  • A 5-year average of -$163.4 million and a median of -$53.0 million in 2024 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: soared 89.18% in 2023, then plummeted 533.33% in 2025.
  • Pfizer's Other financing activities stood at -$185.0 million in 2021, then crashed by 84.86% to -$342.0 million in 2022, then soared by 94.74% to -$18.0 million in 2023, then rose by 22.22% to -$14.0 million in 2024, then plummeted by 207.14% to -$43.0 million in 2025.
  • Per Business Quant, the three most recent readings for PFE's Other financing activities are -$43.0 million (Q4 2025), -$38.0 million (Q3 2025), and -$21.0 million (Q2 2025).